Responses
Regular and Young Investigator Award Abstracts
Clinical Trials Completed
347 KEYNOTE-365 cohort C: pembrolizumab + enzalutamide in patients with abiraterone acetate–pretreated metastatic castration-resistant prostate cancer (mCRPC)—data after minimum of 22 months of follow-up
Compose a Response to This Article
Other responses
No responses have been published for this article.